Resound Vivia 9 60S microRIE vs RxEars Rxi

The ReSound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In our lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #29 of 39 prescription hearing aids tested. This device shows a mixed performance profile. Its standout strength is own-voice comfort, scoring 3.4/5—a solid result that sits 0.70 points above the category average. Speech clarity in quiet environments also performs at category average with a score of 3.4/5. Feedback handling is strong in absolute terms at 4.2/5, though this falls 0.52 points below the category average, reflecting the high bar set by competing prescription devices. The Vivia 9's most notable weakness is speech understanding in noisy environments, where it scored just 1.1/5—a low result that trails the category average by 0.96 points. Music streaming performance is mixed at 2.6/5, sitting slightly below average. These limitations are worth considering given the premium price positioning. For listeners who prioritize comfortable own-voice perception and primarily encounter quieter listening situations, the Vivia 9 may be suitable. However, those frequently in challenging noise environments should note that several alternatives in this price range—including the Phonak Sphere Infinio and Oticon Intent—deliver stronger overall performance in our testing. Budget-conscious shoppers may also find comparable sound quality at lower price points with options like the Jabra Enhance Pro 20 at Costco.

The RxEars Rxi is a budget-priced prescription hearing aid in an invisible-in-ear style, earning an A grade with a SoundScore of 4.1/5 in our lab testing. At $499, it ranks #24 of 39 prescription hearing aids tested, placing it in the top 59% of its category. This device demonstrates notable strengths in speech understanding in quiet environments, scoring 4.3/5—a strong result that sits 0.89 points above the category average of 3.40/5. Feedback handling is excellent at 4.7/5, providing stable performance during movement without the whistling that can plague some hearing aids. Speech in noise performance is mixed at 2.1/5, essentially matching the category average. The RxEars Rxi has significant limitations to consider. Own-voice comfort scores low at 1.6/5, falling 1.10 points below the category average—users may notice their own voice sounds unnatural or boomy. Music streaming is not supported, scoring 0.0/5, which is 2.76 points below the category average. This device uses disposable batteries rather than rechargeables. The RxEars Rxi is best suited for users who prioritize discreet cosmetics and clear speech understanding in quieter settings, and who don't need music streaming capabilities. Those sensitive to own-voice quality or who frequently listen to streamed audio should explore alternatives.